We have investigated the effects of the monoclonal antibodies against the cell surface molecule Mac-i on C3bi-mediated rosetting and IgG-mediated rosetting and phagocytosis by human peripheral blood monocytes. Highly purified M1/70 F(ab')2, used in the fluid phase, inhibited both monocyte functions. Half-maximal C3bi rosette inhibition occurred at a concentration of 2 nM F(ab')2 Mi/70. An 
Introduction
The mAb M1/70 recognizes a two-chain, cell surface glycoprotein on mouse and human leukocytes termed Mac-I (1, 2) . This antigen is a member of a family of cell surface molecules which are heterodimers of noncovalently linked polypeptides.
Although each member of the family has a unique a chain, the 3 chains of all these molecules are apparently identical. The Mac-I antigen is expressed on granulocytes, monocytes, natural killer cells, and some B and T lymphocytes and has been functionally identified with the type 3 complement receptor (CR3)' and the iC3b receptor (3) . M1/70 and certain other antibodies that recognize Mac-i inhibit the binding of iC3b-coated erythrocytes (EC3bi) to leukocytes. Moreover, cells from patients lacking this membrane antigen fail to rosette with EC3bi. Some studies have attributed other inhibitory properties to monoclonal antibodies against Mac-1. Arnaout et al. (4) showed that the IgG2a mAb Mo-I (which recognizes Mac-i) and its Fab fragment inhibited IgG-Fc receptor-mediated phagocytosis as well as EC3bi rosetting (4) . We have shown that M 1/70 inhibited the binding of fibronectin-coated microspheres to monocytes and PMN (5) , and Ezekowitz et al. (6) have shown that Mo-I and M 1/70 inhibited zymosan binding to monocytes and macrophages. Similar inhibition of zymosan phagocytosis has been found by Ross et al. (7) , who showed that some anti-Mac-I mAb also could inhibit the ingestion of unopsonized rabbit erythrocytes. These studies suggest that Mac-I plays an important role in the general adhesive properties of leukocytes, since it is unlikely that each of these inhibitory properties of the anti-Mac-I antibodies can be ascribed to disruption of a single receptor-ligand interaction. This hypothesis is supported by studies in patients deficient in Mac-1. These patients' cells exhibit impaired chemotaxis, aggregation, and substrate adherence in addition to their inability to rosette with iC3b-coated particles.
In this study we have examined the mechanism by which anti-Mac-i antibodies interfere with cellular functions not obviously dependent on soluble ligand interactions with the Mac-i molecule. We have studied the inhibition of IgG-mediated rosetting and phagocytosis by M 1/70 and Mo-I in detail. We have shown that both Mo-I and M 1/70 F(ab')2, which do not interact at all with monocyte Fc receptors, inhibit IgGmediated erythrocyte binding and phagocytosis. Binding studies with monomeric and multimeric IgG showed that M 1/70 inhibited multimeric IgG binding while having no effect on monomeric IgG binding to the Fc receptor. Aggregated IgG was able to inhibit the binding of '251-M1/70 to monocytes by almost 40%, while it had no effect on the binding of monoclonal anti-CRi . This suggested that some, but not all Mac-I molecules were associated with IgG Fc receptors. By adhering M1/70 F(ab')2 to surfaces, we have been able to distinguish Mac-i molecules involved in C3bi rosetting from those involved in IgG-mediated phagocytosis. Adherent M 1/70 F(ab')2 modulated CR3 function, as previously reported (3) . However, this modulation of Mac-ito the adherent surface ofthe monocytes did not affect either IgG receptor-mediated phagocytosis or the continued potent inhibitory effect of fluid-phase M 1/70 F(ab')2 on this process. Under these conditions, 40% of cell surface Mac-I antigen remained on the apical membrane of monocytes plated onto M1/70 bearing surfaces, despite the loss of 75-90% of the cells' ability to bind EC3bi. We suggest that there are diffusable and nondiffusable forms of the antigen recognized by M 1/70 in the monocyte membrane. The diffusing molecule is associated primarily with CR3 function; ligation of the nondiffusing form by M 1/70 is associated with inhibition of IgG Fc receptor function.
Methods

Monoclonal antibodies
The cell line producing M1/70 was obtained from the American Type Culture Collection, Rockville, MD (ATCC No. TIB 128). The cells were grown in Dulbecco's minimal essential medium (DME) supplemented with 15% fetal calf serum, 4 mM glutamine, 20 mM Hepes, penicillin, gentamicin, and amphotericin. Conditioned medium was harvested, and the rat IgG2b purified by a modification of the method of Ault and Springer (1) . After DEAE-Sephacel chromatography as described, three distinct antibody containing peaks were found, with the majority of the M1/70 eluting at 0.2 M NaCl. This peak was pooled, concentrated, and applied to a 500-ml Biogel AO.5m column (Bio-Rad Laboratories, Richmond, CA). The antibody peak was again pooled and concentrated and then digested for 24 h with pepsin as described (8) . The pepsin digest was reapplied to the Biogel AO.5m column, and the column fractions were assayed for the presence of F(ab')2 and intact IgG by SDS-PAGE (9) . Fractions containing F(ab')2 but little intact IgG were pooled and applied to a 600-ml Sephadex G150 Superfine column (Pharmacia Fine Chemicals, Piscataway, NJ). The column was again assayed by SDS-PAGE, and fractions which contained F(ab')2 but no visible intact IgG by silver staining were pooled. This pool was assayed by SDS-PAGE and found to contain no intact IgG (Fig. 1) . Moreover, on a Western blot (10) capable of detecting 4.5 ng of IgG, no intact IgG was seen on electrophoresis and transfer of 1.5 lAg ofthe F(ab32 pool. Thus, the F(ab)2 M1/70 contained < 0.3% intact IgG. Mo-I ( 1i) ascites was the kind gift ofDr. R. F. Todd III, University ofMichigan School ofMedicine. IgG Mo-I was purified by sequential octanoic acid (12) and protein A-Sepharose purification. F(ab')2 were prepared as described (13) IgG of the monoclonal anti-CR 1 3D9 was purified as described (14) . OKM 1 was purchased from Ortho Diagnostics, Raritan, NJ.
Cells
Monocytes were obtained from the buffy coats from whole units of blood by centrifugation on cushions of Ficoll-Hypaque followed by counter current elutriation as described (15) . 85-95% of cells in all preparations of monocytes stained with nonspecific esterase. In all experiments, cells were used on the day of purification. Monocytes were washed three times in RPMI-1640 containing antibiotics, but without serum, before use in experiments.
Phagocytic targets. Sheep erythrocytes (E) were obtained, washed and sensitized as previously described (16) . Except where indicated, E were opsonized with a 1:500 dilution ofrabbit anti-E IgG (EA). EC3bi were prepared as previously described (16) from E sensitized with rabbit IgM, guinea pig C1, and the human complement components C4, C2, and 25 U of C3, prior to incubation with EDTA and factors H and I. The EA bore -10,000 molecules of IgG/E and the EC3bi bore -20,000 molecules of C3/E. Protein coating ofphagocytosis chambers. In some experiments, monocytes were incubated in Labtek chambers (Miles Scientific, Naperville, IL.), which had been precoated with various proteins. For coating with M1/70 F(ab')2 or albumin, Labtek slides were washed and coated with poly-L-lysine (Sigma Chemical Co., St. Louis, MO) exactly as previously described for glass coverslips ( 17) . Thereafter, poly-L-lysine-coated chambers were incubated with glutaraldehyde, and then with various concentrations of M1/70 F(ab')2 or with 50 ;Ig/ml bovine serum albumin (BSA) as a control. After 1 h at room temperature, wells were washed, and residual glutaraldehyde activated sites were quenched by incubation with 0.1 M glycine, 1% BSA, pH 7.5.
Phagocytosis and adherence assays. Phagocytosis and adherence assays were performed by a minor modification of a previously described method (1 1). Briefly, 1.5 X 105 monocytes were allowed to adhere to protein coated or uncoated Labtek chambers for 30 min at 37°C. Fluid phase anti-Mac-I F(ab')2, control antibody, or buffer was added to the cells for 15 min. To prevent interaction of EC3bi with CR1 (18) during EC3bi adherence assays, 10 Mg/ml of monoclonal 3D9, an antibody that recognizes CR1 and inhibits CRI-mediated rosettes (19) , was included at this step. This assured that EC3bi were binding only to CR3. Anti-CRI was not routinely included in EA phagocytosis assays; 3D9 is known to have no effect on EA phagocytosis (14) . Next, lX I07 EA or EC3bi were added and centrifuged onto the monocyte monolayer at 50 g. After 30 min more at 37°C, adherence or phagocytosis was quantitated as previously described (15) . The number ofE bound to 100 monocytes is the attachment index (Al); the number of E ingested by 100 monocytes is the phagocytic index (PI).
IgG binding studies. Quantitation of IgG Fc receptors on monocytes incubated in the presence or absence of M 1/70 F(ab)2 was performed as described (20 30 ,ug of unlabeled monomeric IgG, a concentration previously determined to saturate Fc binding. Cells were incubated for a further 45 min at 37°C, removed from incubation, and centrifuged at 12,000 g through Versilube F-50 (General Electric Co., Waterford, NY). 1251I associated with the monocyte pellet was quantitated by aspirating the supernatant, cutting the tubes, and counting the cell pellet.
In some experiments aggregated IgG was used to assess IgG Fc receptor function. IgG was aggregated and aggregates separated from monomeric IgG as described (21), using an additional Biogel A5M (Bio-Rad Laboratories) chromatography step to separate aggregated from monomeric IgG. Human IgG at 5-10 mg/ml was incubated at 63°C for 15 min. The IgG was centrifuged at 100,000 gfor 60 min, and the bottom half of the centrifuged tube, excluding the insoluble pellet, was applied to a 500-ml Biogel A5m column. Protein that chromatographed in the void volume ofthe column (> 1.8 X 106 D) was used as aggregated IgG. Aliquots of this material were radiolabeled or fluoresceinated as described (22 Bound radiolabel was quantitated after a 1-h incubation at 4°C by extensive washing of the plate-adherent cells with cold PBS, followed by cell solubilization with 1 ml of 0.1 M NaOH containing 1% SDS. . Some of these antibodies also inhibit IgG-mediated phagocytosis by monocytes and PMN (4, 24). We have confirmed that M 1/70 F(ab')2 and Mo-I F(ab')2 have both these properties, inhibiting both EC3bi rosettes and EA phagocytosis (Figs. 2 and 3). Inhibition of C3bi rosettes occurred at somewhat lower concentrations of M 1/70 than equivalent inhibition ofphagocytosis. 50% inhibition of EC3bi rosettes occurred at a concentration of0.2 ,ug/ml F(ab')2 (2 nM), whereas equivalent inhibition of EA phagocytosis required 0.7 yg/ml (7 nM) M1/70 (Fig. 2 ). M1/70 F(ab')2 inhibited EA rosettes as well as phagocytosis, with half-maximal inhibition at 10 nM. The inhibition of EA binding was not due to nonspecific blocking ofthe Fc receptor since the F(ab')2 preparation contained < 0.003 ,ug/ml of intact IgG at this concentration. Mo-1 F(ab')2 inhibited EC3bi rosettes at lower concentrations than M 1/70, since half-maximal rosette inhibition occurred at 0.3 nM (Fig. 3) . In contrast, much more Mo-1 than M 1/70 was required to inhibit EA rosettes, with 50% inhibition requiring -70 nM Mo-1. Inhibition of EA phagocytosis also occurred with Mo-1 (Fab')2, and half-maximal inhibition required 100 nM F(ab')2. Intact IgG Mo-1 inhibited EA rosettes with an ID50 of 0.3 nM, equivalent to its effect on EC3bi rosettes. This results from IgG Fc binding to the highaffinity IgG receptor on monocytes (25) . The effect of Mo-I F(ab)2 on EA binding and phagocytosis did not result from residual intact IgG in the F(ab')2 because no residual intact IgG was detectable on Western blots. Moreover, there was no effect of solid-phase Mo-I F(ab')2 on EA rosettes (see below) whereas as little as 0.05 ug/ml intact IgG Mo-I attached to a solid phase completely inhibited EA rosettes. F(ab')2 3D9, a monoclonal antibody to CR1, and whole IgG OKM1, another antibody that recognizes Mac-I but does not inhibit EC3bi rosettes (3), did not affect EA phagocytosis when used in the fluid phase. The inhibition of EA rosettes and phagocytosis by Ml1/70 could not be overcome by increasing the amount of IgG used to sensitize the E to a maximal subagglutinating dose (Fig. 4) . (27) and monomeric IgG inhibits the binding of erythrocytes opsonized with human IgG (27, 29) , which suggests that this is the receptor that mediates binding of both monomeric and aggregated IgG. When the binding of aggregated IgG to monocytes at 37°C was examined, M1/70 had a profound inhibitory effect (Table I) . Because these incubation conditions might lead to both binding and internalization of aggregated IgG (30), we examined the effect ofMl/70 F(ab')2 on the binding of aggregated IgG at 0°C. The F(ab')2 inhibited the binding of 125I-labeled aggregated IgG, as it had at 37°C (data not shown). In addition, to ensure that surface binding was examined, aggregated IgG was labeled with fluorescein, which would lose fluorescence in the acidic endocytic vesicle upon internaliza- (31) . Monocyte-bound fluorescence was quantitated by fluorescence flow cytometry in the presence and absence of unlabeled aggregated IgG in buffer or in the presence of 125 nM M 1/70. In both cases, the addition of unlabeled aggregated IgG demonstrated the existence of "specific fluorescence" which was saturable under the experimental conditions (Fig.  6 ). Like the binding of radiolabeled aggregates, but unlike the binding of monomeric IgG, the binding of fluoresceinated IgG aggregates was markedly inhibited by M 1/70 F(ab')2 (Fig. 6 C) . The dose response of antibody showed 50% inhibition of aggregated IgG binding at -8 nM F(ab')2 (Fig. 6 D) Ifthere were a physical association between the two molecules, reciprocal inhibition by their ligands might be expected. Aggregated IgG partially inhibited the binding of radiolabeled M 1/70 to monocytes (Fig. 7 A) . -56,000 molecules of M 1/70 were bound per monocyte at saturation in the absence of aggregated IgG. This number was reduced by 37.2±1.6% (n = 7) by 150 ug/ml aggregated IgG. As shown in Fig. 7 A, increasing the concentration of aggregated IgG from 100 to 250 ,ug/ml had no effect on the ability of aggregated IgG to inhibit M 1/70 binding. Thus, -40% of M 1/70 binding was inhibitable by the prior binding of aggregated IgG to monocytes. As shown in Fig. 7 = 519±31, n = 8). Strikingly, coated wells with even 50 ,ug/ml F(ab')2 did not inhibit EA rosetting or phagocytosis (Fig. 8) .
The PI for monocytes on albumin-coated plates was 245±22 (SEM, n = 18); on F(ab')2-coated plates the PI was 261±30 (n = 8). The Al for EA was similarly unaffected by coating plates with M 1/70 F(ab')2. However, addition of fluid-phase M 1/70 F(ab')2 to cells adherent to wells coated with these same F(ab')2 did inhibit EA phagocytosis, and the dose response of inhibition by fluid-phase M 1/70 F(ab')2 was essentially identical for BSA-and Ml /70-coated plates (Fig. 9) . Experiments with Mo-1 F(ab')2 gave precisely the same results. Plate-bound F(ab')2 inhibited EC3bi binding in a dose-response fashion but had no effect on EA rosetting (Fig. 10) . The effect of platebound Mo-1 on EC3bi rosetting was relatively independent of the amount of C3bi on the target, since similar dose responses of inhibition were seen for EC3bi with AI ranging from 500 to 2,000. EA binding was not affected for targets bearing different amounts of IgG giving AT between 100 and 500. When monocytes were plated onto a surface which had been incubated with 100 ,ug/ml F(ab')2 Mo-1, EC3bi rosettes were inhibited by 80% but EA rosettes were uninhibited compared to BSAcoated surfaces (Fig. 1 1) . Nonetheless, 50 ,ug/ml F(ab')2 Mo-I added to the fluid phase inhibited EA rosettes on both BSAand Mo-1-coated surfaces. Figure 10 . Dose response of inhibition of EC3bi and EA attachment by plate bound Mo-I F(ab')2. Lab-tek chambers were incubated with varying concentrations of Mo-I F(ab')2 as described in Methods. After 2 h of adherence to these surfaces, monocytes were examined for residual binding of EC3bi (.) (n = 3) or EA (v) (n = 2). Solid-phase Mo-I inhibited EC3bi binding by as much as 85%, but had no effect on EA binding.
These experiments suggested that there was a population of Mac-I molecules which remained on the apical surface of monocytes adherent to anti-Mac-i-coated wells. Ligation of these molecules on the apical surface resulted in inhibition of IgG-mediated rosetting and phagocytosis just as it did on monocytes from which no Mac-I antigen had been removed from the apical surface. To test whether this remarkable effect could be abolished by allowing the monocytes to adhere to M 1/70 F(ab')2-coated wells for longer periods oftime, a kinetic experiment was performed (Fig. 12) . If apical Mac-I molecules could eventually be brought to the adherent cell surface, the effect of fluid-phase M 1/70 on EA phagocytes would be abolished. When monocytes were adhered to M 1/70 F(ab')2-coated surfaces, subsequent EC3bi attachment to the monocytes was inhibited by 75% at 1 h and by 90% at 4 h, suggesting that some decrease in apically expressed Mac-I had occurred with the longer incubation. On the other hand, even after 4 h, there was no difference in phagocytosis between monocytes plated on BSA and those plated on 45 Atg/ml M1/70 F(ab')2. Moreover, there was no decrease in the ability of fluid-phase Ml1/70 F(ab')2 to inhibit EA phagocytosis, even after the monocytes had been adherent to antibody-coated plates for 4 h. Dose-response curves showed that monocytes plated onto wells coated with 5 jig/ml M 1/70 F(ab')2 were equally inhibited in their binding of EC3bi as those cultured on surfaces coated with 45 jig/ml F(ab')2. However, even the highest dose of antibody of which is involved in the inhibition of EA binding and phagocytosis by anti-Mac-I F(ab`)2. Surface-bound MJ/70 modulates Mac-i antigen. When monocytes were allowed to adhere for 2 h to tissue culture plates coated with an irrelevant antibody (3D9), 39,000 molecules of '25I-M1/70 bound per cell at 4°C (Table II) . In these antigen modulation experiments, intact M 1/70 IgG was used to coat the surface of the tissue culture dish. It has been suggested that the use ofintact IgG rather than F(ab')2 creates a tight junction between the monocyte and the plastic, which prevents diffusion of the radiolabelled probe to the adherent surface of the cell (33). This was confirmed for both 3D9 and M1/70 IgG in our system, because of the presence of "black holes" on fluorescence microscopy in experiments performed as described by Wright and Silverstein (33) . This demonstrated that fluoresceinated anti-mouse IgG was unable to diffuse below the adherent monocytes plated onto surfaces nonspecifically coated with IgG. As described above, 3D9 does not block the binding of M1/70 to monocytes in the fluid phase. Thus the difference between the number of M 1/70 bound specifically to adherent monocytes plated onto 3D9-coated surfaces (39,000 per cell) and to fluid-phase monocytes (56,000 per cell) represents the inaccessibility of Mac-I on the adherent monocyte undersurface to fluid-phase '251-M1/70.
Adherence to tissue culture wells coated with 5 ,g/ml M 1/70 IgG, which maximally inhibited EC3bi rosettes, reduced '251-M 1/70 binding by only 45% after 2 h of adherence (Table II) . As was true for EC3bi rosetting, somewhat fewer antibody molecules bound to cells that had been incubated on an M 1/70-coated surface for 4 h (40% of control). Treating cells with 10 sg/ml cycloheximide, to prevent synthesis of new Mac-I antigen during the adherence period, did not affect '251-M1/70 binding to cells plated on antibody coated or control wells. Thus these data demonstrate that a significant amount of M1/70 antigen remained on the apical surface ofthe cell, even after prolonged adherence to M 1/70-coated surfaces. The absence of an effect of cycloheximide on M 1/70 binding suggested that newly synthesized and inserted Mac-I antigen does not affect the distribution of this cell surface antigen during the course of these experiments. (27) . One receptor of 72 kD (28) has high affinity for monomeric human IgG 1 and IgG3 (20 phase M 1/70, these data suggest that the nondiffusing pool of Mac-I antigen which remains on the apical surface of cells adherent to Mo-I or M1/70-coated surfaces and the Mac-I antigens involved in Fc receptor function are identical.
We suggest that the Mac-I molecules involved in phagocytic function, unlike the majority of the molecules involved in C3bi receptor function, are not freely diffusing in the monocyte membrane (Fig. 13) . In this respect these molecules would be similar to the C3 receptors of resting mouse peritoneal macrophages, which also do not diffuse in the plane of the membrane (39) . This explanation would be consistent with both the different dose-response curves for the fluid-phase Mo-I and M1/70 effects on complement and IgG mediated functions, and with the apparent lack of effect of solid-phase F(ab')2 on IgG Fc receptor function. Thus, comparison of inhibition of rosetting and phagocytosis by fluid-phase and solid-phase anti-Mac-I antibodies suggests that there are two functionally distinct membrane molecules which express the Mac-I antigen. The molecules involved in C3bi rosetting but not (42) . However, our work represents the first demonstration of a biological function restricted to the nondiffusing subset of a membrane antigen. If enhancement of receptor aggregation in general is a property of the nondiffusing Mac-i molecules, the in vitro abnormalities of Mac-I -deficient cells, as well as many of the clinical manifestations of Mac-i deficiency, may result quite specifically from the loss of this form of the membrane molecule. This would suggest that the intramembranous and transmembrane association of this molecule will be of particular biological interest.
